GILD reports positive results for Livdelzi in PBC patients with mild ALP elevation Jun 2, 2026 08:30AM
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC) Jun 2, 2026 08:30AM
Gilead's Livdelzi shows sustained liver marker improvement in PBC study May 27, 2026 02:00AM
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar) May 27, 2026 02:00AM
FDA approves Gilead's Hepcludex as first HDV treatment in U.S. May 22, 2026 02:00PM
View Older Stories

May 22, 2026 02:00PM FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
May 22, 2026 07:47AM Gilead receives EU panel backing for Trodelvy in breast cancer treatment
May 22, 2026 07:47AM Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
May 21, 2026 05:00PM New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
May 21, 2026 09:30AM Gilead Sciences completes $3.15 billion Tubulis acquisition
May 21, 2026 09:30AM Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
May 21, 2026 05:55AM Gilead Sciences extends WHO partnership to fight visceral leishmaniasis
May 21, 2026 03:30AM Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
May 13, 2026 08:30AM Gilead to present 29 abstracts on liver disease treatments at EASL 2026
May 13, 2026 08:30AM Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
May 1, 2026 06:00AM Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences
Apr 28, 2026 08:45AM Gilead Sciences completes $7.8 billion Arcellx acquisition
Apr 28, 2026 08:45AM Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
Apr 22, 2026 04:05PM Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
Apr 14, 2026 12:03PM PEPFAR and Global Fund expand lenacapavir access to 1 million more people
Apr 14, 2026 12:00PM PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access
Apr 7, 2026 09:33AM Gilead to acquire Tubulis for up to $5 billion to expand cancer pipeline
Apr 7, 2026 08:30AM Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
Mar 23, 2026 06:15PM Gilead Sciences to acquire Ouro Medicines for up to $2.2 billion
Mar 23, 2026 06:15PM Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
Mar 2, 2026 08:30AM Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia
Feb 23, 2026 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Feb 10, 2026 04:02PM Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend
Jan 27, 2026 04:05PM Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
Jan 21, 2026 05:00PM Gilead's Trodelvy plus Keytruda shows 35% reduction in cancer progression
Jan 21, 2026 05:00PM New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negativ
Dec 24, 2025 07:00AM Gilead Sciences acquires Repare drug candidate for up to $30 million
Dec 22, 2025 04:05PM Gilead Sciences to Present at Upcoming Investor Conference
Dec 22, 2025 08:02AM Gilead exercises option for Assembly Bio's herpes treatment programs
Dec 22, 2025 08:00AM Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
Dec 19, 2025 02:21PM GILEAD reaches three-year pricing agreement with US government
Dec 19, 2025 02:21PM Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
Dec 18, 2025 08:30AM Gilead Sciences names Keeley Wettan as executive vice president
Dec 18, 2025 08:30AM Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
Dec 9, 2025 08:30AM Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
Dec 8, 2025 02:53AM Kite reports 96% response rate in multiple myeloma trial
Dec 6, 2025 02:00PM Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
Nov 24, 2025 08:30AM Gilead Foundation Commits Over $3 Million to Address Food Insecurity
Nov 18, 2025 05:09AM Gilead ships first lenacapavir doses to sub-Saharan Africa
Nov 18, 2025 05:00AM Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
Nov 7, 2025 08:30AM Gilead's Trodelvy fails to meet primary endpoint in breast cancer study
Nov 7, 2025 08:30AM Gilead Provides Update on Phase 3 ASCENT-07 Study
Nov 7, 2025 08:01AM GILD presents long-term data on Livdelzi for liver disease treatment
Nov 7, 2025 08:00AM Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression
Nov 4, 2025 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Nov 3, 2025 09:10AM Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
Oct 31, 2025 08:00AM Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)
Oct 23, 2025 08:00AM Gilead to present liver disease data at AASLD conference
Oct 23, 2025 08:00AM Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta
Oct 19, 2025 08:30AM Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
View Older Stories